10x Genomics’ Post

Happening today! Integrated Multi-omics Analysis Reveals Systemic and Localized Metabolic Disruptions in Colorectal Cancer, a webinar presented by Dr. Ethan Stancliffe. Tune in a 12pm Eastern to learn about Panome Bio's approach to integrated multi-omics analysis and discover novel insights into the underlying mechanisms of colorectal cancer! Watch Here: https://lnkd.in/gtZcAqXf #multiomics #metabolomics #proteomics #transcriptomics #cancerresearch

Today marks the first day of Myeloma Action Month. Multiple Myeloma is a cancer of bone marrow plasma cells, and it is the second most common blood cancer. Despite advancements in the treatment of Multiple Myeloma, there remains a significant unmet need for novel therapies. At Kronos Bio we are working diligently to progress our new development candidate, KB-9558, which targets the lysine acetyltransferase (KAT) domain of p300, a critical node of the Interferon regulatory factor 4 (IRF4) transcription regulatory network (TRN). IRF4 is a key driver in multiple myeloma. #MyelomaActionMonth

Phase 1 trial with PSCA-CAR T cell therapy in patients with mCRPC - Saul Priceman, PhD Lior Pachter Prostate Cancer Foundation #Cancer #ClinicalTrial #OncoDaily #Oncology #ProstateCancer

Did you miss our webinar on PIM1 in prostate cancer? Don't worry, you can view it any time, on-demand on our website at the link below: Watch here: https://hubs.ly/Q02C3qtT0 Contact Panome Bio today to find out how we can provide industry leading biomarker and mechanism analysis for your cancer research. #cancerresearch #prostatecancer #metabolomics #lipidomics

#HaveYourSay OPTIMA is an Innovative Medicines Initiative (IMI) project that uses artificial intelligence (AI) to improve care for patients with lung, prostate and breast cancer, which ELF is proud to be a part of. OPTIMA Oncology would like patients and patient representatives to help them decide on the most important research priorities in lung cancer and breast cancer. Learn more at https://ow.ly/nKSe50PWYNa

I highly recommend checking out this study titled "Clinical Translation of Targeted α-Therapy: An Evolution or a Revolution?" 🔎 It explores the advancements in targeted α-therapy and its potential as a game-changer in cancer treatment. The study discusses approved α-therapies, innovative models, and the use of combination treatments. Also, it highlights the ongoing clinical trials for different cancer types, including neuroendocrine tumors and metastatic prostate cancer. Enjoy! #nuclearmedicine #radiotherapy #targetedtherapy

For patients who present with advanced stage cervical cancer, targeted therapies can improve outcomes. Join us for a molecular tumor board as we discuss treatment options for patients with recurrent cervical cancer and how biomarker-directed therapies are transforming the standard of care. #MolecularTumorBoard #PrecisionOncology #CervicalCancer

My latest first-author publication is now available in The Red Journal (Int. J. Rad. Onc. Biol. Phys., IJROBP), the leading journal in radiation oncology field. We identified factors which might help decision making on locally-advanced non-small cell lung cancer (LA-NSCLC) treatment, when considering of immunotherapy on chemo-radiation. Summarised structure and key findings are shown below. Detail can be accessed via: https://lnkd.in/dYhWWteK Please reach out if you are interested; in particular, if our quantitative methodology might be applicable to your research. #RadOnc #MedPhys #LungCancer #NSCLC #Radiotherapy #Immunotherapy

Targeted therapy takes on glioblastoma: Unpacking the power of small molecule inhibitors in clinical trials 🧬 Focused on disrupting key cancer pathways, these inhibitors are a beacon of hope for personalized treatment. Each step brings us closer to transforming glioblastoma care. Discover the future of brain cancer therapy at Medoh Health. 🔍 #GlioblastomaInnovation #TargetedTherapy #MedohHealth

In the April 2024 issue of JNM: >Featured: The Illustrated Post – First in human Pb-212 PSMA-targeted alpha therapy SPECT/CT imaging in prostate cancer >Theranostic potential for an MUC16-targeted antibody for ovarian cancer >Is It Really Happening? F-18 FDG metabolic tumor volume in lymphoma >Discussion with Julie Price: advancing neuroimaging >Theranostics and SBRT in oligometastases …and more!   See the full journal here: https://lnkd.in/e2pHnF-6